Many people in Spain suffer from migraines. It is a headache that can appear with symptoms such as nausea, vomiting or sensitivity to light and sound. In most people, the perception of this sensation develops as a throbbing pain only on one side of the head.
This phenomenon is a very common pathology, however, It can be very disabling in many cases.. One of the main problems with migraines was that, until now, There was no specific medication to prevent it in Spain.
A situation that has currently changed thanks to the Vydura release, the first specific treatment for migraines marketed in our country. Vydura is a pill that, a priori, serves to attack the source of pain effectively. However, The great advance of this new medication is that it also acts as a protector, preventing this disease. so annoying
What is Vydura and how does it stop migraines?
Vydura is the new medication that has reached the market in Spain and that promises to revolutionize the uncertain universe of migraines. It is a pill with very few side effects and that acts on the receptors of a specific protein found in the blood of patients who suffer from this pathology.
The big change it brings is that it is a capsule that acts preventively, but is also very useful against pain. By acting on two sources, it will allow patients to take much less medication than they received until now when they entered the complicated spiral of migraines and headaches that produce the famous migraines.
[Patricia Pozo-Rosich, neuróloga: “El paracetamol no funciona para tratar la migraña”]
It is a medicine that, logically, taken orally and according to experts it is much more effective than conventional treatments. Great news for more than 4 million people suffer from them in Spain. Vydura is a medicine manufactured by the Pfizer laboratory and has countless advantages.
One of them is that it acts very quickly, since Patients who take it begin to feel its effects in just two hours after having taken it. Provides sustained relief for up to 48 hours without the need for rescue medication. Reduces vasodilation and neurogenic inflammation.
Representation of migraine.
Jose Chavesmedical director of Pfizer Spain, assesses the finding as follows: “It represents a great advance in reducing pain and symptoms such as photophobia or nausea, but it is also a preventive treatment for patients who have at least four crises per month.”
Migraines are one of the most disabling diseases that exist in the neurological field according to the WHO. And one of its big problems is that many people who suffer from them do not know how to attack them. Two thirds of people who need preventive treatment in Spain still do not have it. The expectation is that it will be financed for a specific sector of people.
[¿Por qué es tan difícil curar la migraña? Las tres causas detrás del enigma médico]
For now, Social Security will not cover the costs for those adults who use it as a defense treatment, but it will for those who have it prewritten as preventive treatment and who register between 8 and 14 days of migraine per month and three or more failures of previous treatments used for at least three months. The new drug is administered in hospitals, but can also be prescribed by the general practitioner.
The expert Elisa Cuadradofrom the Headache Unit of the Hospital del Mar in Barcelona, explains the effects of migraines and the progress that this medication represents in RTVE: “It doesn’t let you live your life. We are finding very specific targets, but there is still a lot to investigate and there are other avenues to explore and see if they work for refractory people.”
[Doctor Porta, el sabio de la migraña: “Los hombres se quejan bastante más que las mujeres”]
For its part, Pablo Irimiafrom the Spanish Society of Neurology, assesses the advances in this way: “Migraines are the first cause of disability in adults between 16 and 50 years old. We have a risk in patients who suffer frequent migraine attacks who, if they consume many analgesics, may develop a headache due to excessive use of these medications. And this drug, from the evidence we have so far, does not cause this problem.”
Migraines affect about 1 billion people in the world to a greater or lesser extent and are the second cause of disability., the first in women between 15 and 49 years old, according to WHO data. In fact, up to 64% of patients say that it affects their performance during their daily lives. Now, Vydura arrives with the promise of changing things after having already been marketed in more than 40 countries.
Follow the topics that interest you